Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma

• Published in: Targeted oncology Vol. 18; no. 6; pp. 941 - 952
• Main Authors: Wang, Ning, Mo, Zhenxian, Pan, Lu, Zhou, Minhua, Ye, Xiaolan, Liu, Xinjian, Cai, Xiong, Qian, Changgeng, Chen, Feili, Xiong, Yan, Fan, Fushun, Li, Wenyu
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.11.2023; Springer Nature B.V
• Subjects: Biomedicine; Ferroptosis; Hematology; Lymphoma; Medicine; Medicine & Public Health; Nervous system; Oncology; Original Research Article

Background The efficacy of systemic treatment for primary central nervous system lymphoma (PCNSL) is limited because of the blood–brain barrier (BBB) and the ineffectiveness of chemotherapy. The dual PI3K/HDAC inhibitor BEBT-908 has exhibited favorable in vivo distribution and activity in various ca...